An overview of recommendations from the Review of Medicines and Medical Devices Regulation relating to low risk therapeutic goods.

1. Regulatory Reforms at the Therapeutic
Goods Administration (TGA)
Dr Mark McDonald
Assistant Secretary, Regulatory Reforms, TGA
ARCS webinar - MMDR series
28 April 2017

2. About the TGA (briefly)
• Part of the Commonwealth Department of
Health, but separately located and with its own strong external
brand
• HQ in Canberra with 5 satellite offices
• Approx. 700 staff plus 80 contractors: scientists, engineers,
toxicologists, technicians, medical officers, pharmacists, lawyers
and administrative staff
• Budget of $150m pa
• Virtually all of TGA’s operations are cost recovered from industry
fees and charges - unique globally among medicines and device
regulatory bodies
Regulatory Reforms at the Therapeutic Goods Administration 1

3. Locations
• The majority of TGA staff are located at
the Symonston site in Canberra
• This building has combined office space
with extensive scientific laboratories
• Some TGA are co-located with
Department of Health colleagues at the
Department’s Central Office in Woden
• TGA also has staff in Sydney, Melbourne,
Adelaide and Brisbane
Regulatory Reforms at the Therapeutic Goods Administration 2

4. TGA’s role
• Regulate therapeutic goods including prescription, over-the-counter and
complementary medicines, medical devices, biologicals, blood and blood products
• Evaluates therapeutic goods before they are marketed and monitors products once
they are on the market
• Assesses suitability of medicines and devices for export
• Focuses on safety, efficacy and quality
• Works closely with consumers, health professionals, industry and international
counterparts
Regulatory Reforms at the Therapeutic Goods Administration 3

5. Department of Health
Organisational Structure
Secretary
Chief
Operating
Officer
Strategic
Policy
and
Innovation
Health
Benefits
National
Program
Delivery
Health
Products
Regulation
Health
Protection/
CMO
Special Adviser:
Strategic Health
Systems and
Information
Mgt
Regulatory Reforms at the Therapeutic Goods Administration 4

6. Risk management
All therapeutic goods have some level of risk
Our role is to see that benefits outweigh known risks Management
of uncertainty is a greater challenge
TGA’s approach to risk management involves:
• identifying, assessing and evaluating the risks posed by
therapeutic products
• applying any measures necessary for treating the risks posed
• monitoring and reviewing risks over time
Regulatory Reforms at the Therapeutic Goods Administration 5

7. Can regulators manage uncertainty well
enough?
• Regulators have frameworks for assessing benefits and harms (risk) but
less with uncertainty
• Uncertainty and harms can be confused, with negative consequences
for decision making
• A balance between the two is needed, combining the science with an
appropriately designed regulatory framework
Regulatory Reforms at the Therapeutic Goods Administration 6

8. Review of Medicines & Medical Devices Regulation
• Expert Panel commenced late 2014 after most of 2014 in pre-work
• Review process included discussion papers, submissions and interviews by the panel
• Two reports on medicines and devices and complementary medicines and advertising
released during 2015 with 58 recommendations
• Following release of the reports, workshops held with key stakeholders by the Department
to get feedback on recommendations
• Health Minister took preferred position to Cabinet
• Government response was publicly released on 15 September 2016
Regulatory Reforms at the Therapeutic Goods Administration 7

9. Key principles endorsed by Government
• The Australian Government retain responsibility for approval of
therapeutic goods rather than automatically accepting international approvals,
but TGA needs to:
− make greater use of overseas evaluations
− introduce greater flexibility in approval pathways for both medicines and
medical devices
− more appropriately align level regulation with the actual risk posed by
certain types of products
Regulatory Reforms at the Therapeutic Goods Administration 8

10. Further reviews to be undertaken
In scope
• Medicines (and chemicals) Scheduling Policy Framework
• Schedule 3 medicine advertising guidelines
• Review regulation of lower-risk medicines
Proposed process
• Document the basis of current approaches, approach of other
regulators, and alternative frameworks
• Conduct stakeholder workshops
• Consultation papers and formal feedback on options
• Provide advice to Minister on options
• Ministerial decision, change to regulations?
Regulatory Reforms at the Therapeutic Goods Administration 9

11. To Regulate or Not to Regulate
• TGA regulatory frameworks
– Exempt goods
– Excluded goods
• Consumer goods (ACCC)
Regulatory Reforms at the Therapeutic Goods Administration 10

12. Guiding principles of the review
• Not our intention to fundamentally change the definition of a medicine or medical device.
• What is the purpose of our regulation
• Considered the concept of ‘regulatory familiarity’ of particular products
• Recognised that moving some product types to regulation by Food Standards Australian
New Zealand (FSANZ) or under the National Industrial Chemicals Notification and
Assessment Scheme (NICNAS) are not necessarily options that provide for decreasing
regulation
• Australian Consumer Law provides for default Australian Competition and Consumer
Commission (ACCC) oversight of all consumer goods in Australia under Australian
Consumer Law, including therapeutic goods used by consumers
Regulatory Reforms at the Therapeutic Goods Administration 11

13. Next steps: Identify product types in scope
• Water-soluble vitamins and minerals, homeopathic
products?
• Medicated lozenges
• Primary and secondary sunscreens
• Disinfectants, medicated soaps and toothpastes,
nappy rash treatments
• Some class one medical devices
• Sanitary tampons
• Other products?
Regulatory Reforms at the Therapeutic Goods Administration 12

14. Next steps: Develop a risk framework
• How to define “low risk”?
• For medicinal products, this could include parameters such as:
– safety of the ingredients
– route of administration
– risk associated with the claims including labelled use
– nature of the condition being treated/ prevented
– nature and number of the population using the product
– impact of poor manufacturing quality on safety/ efficacy
• Regulatory “familiarity” does this reduce uncertainty or actual risks?
• What is the ability of sponsors to objectively self-assess the product ?
• Look at international experience / alternative regulatory approaches
Regulatory Reforms at the Therapeutic Goods Administration 13

15. Low Risk Classification System
Rate
Experts
qualitatively rate
a product on
each of six
criteria
Combine
Take average of
ratings on each
criterion
Weight
Multiply
averaged ratings
by criteria
weights
Sum
Calculate a
product’s Score
as sum of
weighted ratings
Classify
Low Risk if
Score Less than
Threshold
• To objectively determine if products are ‘low risk’ the TGA developed a Low Risk
Classification System (LRCS) in consultation with experts in this area from the University
of Melbourne
• The basic principle of the LCRS
• This approach is increasing used to publicly rate hotels and restaurants
(e.g. on “Trip Advisor”), car smash repairers and even health care providers
“Wisdom of crowds” Linear model
Regulatory Reforms at the Therapeutic Goods Administration 14

16. So what was considered ‘low risk’
In the context of Recommendation 14 of this review the following was considered ‘low risk’:
• Ear candles
• Nappy rash creams
• Antiperspirants
• ‘Low risk’ OTC medicines
• Hard surface disinfectants
• Sunscreens
• Tampons and menstrual cups
TGA developed a range of possible options that represent potential future regulatory
approaches.
Regulatory Reforms at the Therapeutic Goods Administration 15

17. ‘Low risk’ OTC medicines
A number of well-known OTC products that have a long history of use at particular
ingredient levels and dosage forms have been identified as ‘lower risk’.
These product types include:
• Registered desensitising toothpastes
• Antiseptics for first aid treatment of minor cuts and abrasions
• Lozenges for relief of sore throats
(these contain anti-microbial active ingredients)
• Antacids – containing carbonates, hydroxides, silicates, and/or alginates (but not
medicines containing a proton pump inhibitor or H2 antagonist)
• Salicylic acid plasters for removal of corns and warts
• Menthol-based inhalers and chest rubs
Regulatory Reforms at the Therapeutic Goods Administration 16

18. ‘Low risk’ OTC medicines
Product types continued:
• Antiseptic mouth washes
• Acne treatments containing benzoyl peroxide
• Rubefacient preparations for minor aches and pains of muscles (e.g. methyl salicylate,
menthol, capsicum) but not creams or ointments containing a non-steroidal anti-
inflammatory medicine
• Certain laxatives
Options
• Maintain the status quo regulation
• Review the eligibility of active ingredients to become Listable
Regulatory Reforms at the Therapeutic Goods Administration 17

19. Hard surface disinfectants
Issues identified by stakeholders with the current framework include:
• Regulatory requirements are confusing
• Timeframes for application processing are very long
• Safety evaluations for different formulations are expensive
Range of options:
• Maintain the status quo regulation of hard surface disinfectants
• Streamline the regulatory framework for hard surface disinfectants
• Develop a series of monographs
• Approval process for new ingredients
• Declare hard surface disinfectants not to be therapeutic goods
Regulatory Reforms at the Therapeutic Goods Administration 18

20. Sunscreens
Issues identified by stakeholders with the current
framework include:
• Medicine level GMP
• Process for review of new ingredients slow
and expensive
• Application of pharmacopeial standards for
all ingredients
• Different levels of regulation confusing
Range of options:
• Maintain the status quo regulation of sunscreens
• Streamline the regulatory pathways for sunscreen
regulation
• Prevent all secondary sunscreens from making
SPF claims
• Creation of a GMP standard for primary
sunscreens
• New ingredient approval process
• Alternative ingredient standards for excipients
• Exclude all sunscreens from the regulatory
framework
Regulatory Reforms at the Therapeutic Goods Administration 19

21. So what was considered ‘low risk’
Recommendation 23 was the review of Class I medical devices.
• To maintain international harmonisation we did not want to fundamentally change the
classification system for medical devices
• Whilst trying to identify candidates for consideration it was recognised that there is a
significant number of potentially non therapeutic goods in the ARTG
• Proposal is to clean up the ARTG to remove the ‘white noise’ before taking a look at
those remaining Class I medical devices, and consider any further regulatory changes
Regulatory Reforms at the Therapeutic Goods Administration 20

22. Proposed next steps for Class I medical devices
• Systematic review of ARTG to identify non therapeutic goods
• Engage with States and Territories Health department procurement branches
• Update the Excluded Goods Order
• Review the Class I medical device ARTG entry process
Regulatory Reforms at the Therapeutic Goods Administration 21

23. So what was considered ‘low risk’
In the context of Recommendation 48 of this review the following was considered ‘low risk’:
• Aromatherapy products
• Rehydration or formulated sports products
• Certain vitamins and minerals
• Homoeopathic products
Again, TGA developed a range of possible options that represent
future regulatory approaches.
Regulatory Reforms at the Therapeutic Goods Administration 22

24. Aromatherapy products
Aromatherapy uses essential oils for the purpose of altering one's mood, cognitive,
psychological or physical wellbeing.
Issues with the current approach include:
• the purpose of a product containing an essential oil determines which part of government
regulates it
• The difference between therapeutic and cosmetic products can be confusing
Range of options:
• Maintain the status quo regulation of aromatherapy products
• Exemption from listing in the ARTG and/or GMP
• Declare essential oils not to be therapeutic goods
Regulatory Reforms at the Therapeutic Goods Administration 23

25. Rehydration or formulated sports products
Issue with the current approach include:
• confusion at the food-medicine interface
• the dosage forms for these products range from sachets of oral powders and
effervescent tablets to ice blocks and ready to drink solutions
• rehydration products are similar in composition and presentation to electrolyte drinks,
also known as sports drinks, which are beverages designed specifically for the rapid
replacement of fluid, carbohydrates, and electrolytes
Proposed further action:
• Review of rehydration products on the ARTG to remove food claims to ensure clear
demarcation between sports drinks and therapeutic rehydration products
Regulatory Reforms at the Therapeutic Goods Administration 24

26. Certain vitamins and minerals
Not all of these supplements represent equal risk
• Water soluble vitamins (for example vitamin C) have a lower
risk profile than fat soluble vitamins (for example vitamin A)
as they are readily excreted from the body, whereas fat
soluble vitamins have been associated with toxicity
• Similarly minerals such as calcium have a lower risk profile,
compared to higher risk minerals which are included in a
schedule of the Poisons Standard, such as some iron
preparations
Regulatory Reforms at the Therapeutic Goods Administration 25

27. Certain vitamins and minerals
Issues with the current approach include:
• the introduction of Standard 1.2.7 – Nutrition, Health and Related Claims in 2013 by
Food Standards Australia New Zealand (FSANZ) has caused a significant change to the
food/medicine interface
• Some vitamin and mineral products are more akin to food or dietary supplements than
medicines
Range of options:
• Maintain the status quo regulation of vitamins and minerals
• Exemption from listing in the ARTG and/or GMP
• Declare certain vitamins and minerals not to be therapeutic goods
Regulatory Reforms at the Therapeutic Goods Administration 26

28. Homoeopathic products
• Homoeopathic preparations (4X and above) are exempt from
being entered in the ARTG if they:
– are not required to be sterile
– do not include ingredients of human or animal origin, and
– do not make reference to serious diseases or conditions.
• Preparations that meet these conditions are also exempt from
requiring the manufacturer to hold a GMP licence
Regulatory Reforms at the Therapeutic Goods Administration 27

29. Homoeopathic products
Issues identified with the current approach include:
• Questionable evidence
• Inconsistency in regulation for level of claims being made, ie homoeopathic products
making high level claims must be listed. Other non homoeopathic products making high
level claims are required to be registered
Range of options:
• Maintain the status quo regulation of homoeopathic products
• Serious therapeutic claims must be supported by scientific evidence
• Exemption from listing in the ARTG and/or GMP
• Declare homeopathic products not to be therapeutic goods
Regulatory Reforms at the Therapeutic Goods Administration 28

30. The Scheduling Policy Framework - background
• The SUSMP is the basis by which public access to medicines and chemicals is controlled.
• Substances are placed into a schedule based on the risk associated with their use.
Progression through the schedules signifies increasing restrictions.
• For medicines: S2, S3, S4 and S8
• For chemicals: S5, S6 and S7
• S9: only available for teaching, research etc
• Decision making powers contained in the Therapeutic Goods Act 1989, i.e. delegates of the
Secretary of the Department of Health make the actual scheduling decisions
• The SPF provides the risk based decision making principles to be used by the decision
maker – the scheduling decision is captured by the SUSMP
• Implementation of the SUSMP is through relevant State and Territory legislation
Regulatory Reforms at the Therapeutic Goods Administration 29

31. SPF - considerations for reform
Policy recommendations
Governance 1 Split the SPF into a policy document and a guidance handbook.
2
Establish an informal working group comprising state and territory representatives,
industry, healthcare professionals and consumers to meet as required to provide advice
on possible amendments to the SUSMP
Interim decision 3
Amend the Therapeutic Goods Regulations to allow general public consultation on the
interim decision and where appropriate, enable the time available for submissions to be
extended.
Timing of
decision
4
Explore options for establishing a chemicals scheduling delegate in APVMA to streamline
scheduling and marketing authorisation considerations.
Tools for better
management of
rescheduled
substances
5
Create a new Appendix in the Poisons Standard (SUSMP) to enable additional controls or
requirements for Schedule 3 substances to be specified, in particular for substances that
have been down-scheduled from Schedule 4 (prescription only).
Regulatory Reforms at the Therapeutic Goods Administration 30

32. SPF - considerations for reform
Ongoing improvements and development of guidance materials
Decision-making
principles
1
Undertake a trial to assess the value of applicants presenting to the advisory
committees
Risk:benefit value tree 2
Prepare worked examples of the risk:benefit tree for recent scheduling
considerations and determine if there is utility for using as part of scheduling
applications
Proactive consideration
of candidate substances
for rescheduling
3 Implement a system for proactively identifying substances for rescheduling
Parallel processes 4A
Develop a possible mechanism for aligning prescription to OTC medicine
rescheduling applications with applications to TGA for market authorisation Of
products containing the potentially rescheduled substances at OTC medicines
4B Consider options for market incentives for down-scheduling
Regulatory Reforms at the Therapeutic Goods Administration 31

33. S3 (pharmacist only) medicines advertising
• Currently only a limited number of S3 medicines can be advertised – managed
through an appendix to the SUSMP
• The Expert Panel found very diverse views on possible change
– And whether the current situation led to unnecessary GP visits
• Government has asked for more specific consultation to be conducted
• Options canvassed by stakeholders in 2015 workshops, included:
– Make no change to the current system
– Move instead to having a small list of substances forbidden from advertising
– Move to a self-regulatory approach
– Allow “information provision” by industry but not advertising
• Current consultation is asking stakeholders for their feedback on these possible options in order to
develop a new framework for the advertising of these substances
Regulatory Reforms at the Therapeutic Goods Administration 32

34. SPF Reform process
Stakeholder engagement
Consultation paper
Analysis of feedback
Further consultation
if required
Possible implementation of reform
January 2018
Noted SPF review at
December 2016 meeting
Notified of consultation feedback
Endorsement of proposed reform requested
June 2017 meeting
Notified of consultation 2 feedback
September 2017 meeting
Endorsement of revised SPF or other reform
December 2017 meeting
AHMAC
Regulatory Reforms at the Therapeutic Goods Administration 33

35. Questions?
Any questions relating to consultation submissions can be directed to the
Regulatory Reforms Team by email to tgaregreforms@health.gov.au
34

36. Find out more:
www.tga.gov.au/mmdr
MMDR.consultation@health.gov.au
tgaregreforms@health.gov.au